71 related articles for article (PubMed ID: 26107610)
21. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
Yamaguchi T; Kakefuda R; Tajima N; Sowa Y; Sakai T
Int J Oncol; 2011 Jul; 39(1):23-31. PubMed ID: 21523318
[TBL] [Abstract][Full Text] [Related]
22. [Effects of P2Y receptor activation on prostatic cancer cells requiring ERK1/2 or p38 cascade].
Chen L; Fang WG; Heng WJ; You JF
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):146-50. PubMed ID: 15132853
[TBL] [Abstract][Full Text] [Related]
23. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
24. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
25. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
Fischmann TO; Smith CK; Mayhood TW; Myers JE; Reichert P; Mannarino A; Carr D; Zhu H; Wong J; Yang RS; Le HV; Madison VS
Biochemistry; 2009 Mar; 48(12):2661-74. PubMed ID: 19161339
[TBL] [Abstract][Full Text] [Related]
29. MEK1/2 inhibitors block basal and transforming growth factor 1beta1-stimulated JC virus multiplication.
Ravichandran V; Jensen PN; Major EO
J Virol; 2007 Jun; 81(12):6412-8. PubMed ID: 17409139
[TBL] [Abstract][Full Text] [Related]
30. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.
Schirmer A; Kennedy J; Murli S; Reid R; Santi DV
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4234-9. PubMed ID: 16537514
[TBL] [Abstract][Full Text] [Related]
31. MEK1 plays contrary stage-specific roles in skeletal myogenic differentiation.
Jo C; Jang BG; Jo SA
Cell Signal; 2009 Dec; 21(12):1910-7. PubMed ID: 19733237
[TBL] [Abstract][Full Text] [Related]
32. Expression and purification of phosphorylated and non-phosphorylated human MEK1.
Smith CK; Carr D; Mayhood TW; Jin W; Gray K; Windsor WT
Protein Expr Purif; 2007 Apr; 52(2):446-56. PubMed ID: 17175166
[TBL] [Abstract][Full Text] [Related]
33. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
34. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
35. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Wang J; Sai K; Chen FR; Chen ZP
Cancer Chemother Pharmacol; 2013 Jul; 72(1):147-58. PubMed ID: 23645289
[TBL] [Abstract][Full Text] [Related]
36. The protease Omi cleaves the mitogen-activated protein kinase kinase MEK1 to inhibit microglial activation.
Hu Q; Li B; Xu R; Chen D; Mu C; Fei E; Wang G
Sci Signal; 2012 Aug; 5(238):ra61. PubMed ID: 22912494
[TBL] [Abstract][Full Text] [Related]
37. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
[TBL] [Abstract][Full Text] [Related]
38. Fast Mek1 Hit Identification with TRIC Technology Correlates Well with Other Biophysical Methods.
Jeridi S; Rak A; Gupta A; Soule P
SLAS Discov; 2021 Sep; 26(8):1014-1019. PubMed ID: 34238039
[TBL] [Abstract][Full Text] [Related]
39. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
40. [Docking-based virtual screening of MEK1 inhibitors from Chinese herbs].
Li YL; Du ZY; Zheng J
Zhongguo Zhong Yao Za Zhi; 2017 May; 42(10):1951-1956. PubMed ID: 29090556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
